Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Lyft Under 15 RideHailing Stock Draws Market Attention Italys Top Court Rules No Legal Right to Free Tap Water in Hotels Setting Precedent for Hospitality Industry Persistent Systems and Kong Partner to Enhance Security for Enterprise AI Scaling Rubios NATO Assurance on US Troop Deployments Signals Geopolitical Stability for Investors Trump Pressures Bank of America and JPMorgan to Cease Alleged Discrimination Against Conservatives BK Q1 2026 Earnings Strong EPS Surprise of 1326 Amid Stable Market Response PTEN Q1 2026 Earnings NarrowerthanExpected Loss Signals Operational Discipline HRB Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction CION Q1 2026 Earnings EPS Misses Estimates by 174 Stock Declines AIN Q1 2026 Earnings Strong EPS Beat Drives Positive Investor Reaction Onconetix Inc ONCO Edges Higher Amid Consolidation Near Key Resistance Kayne Anderson Energy Infrastructure Fund KYN Nears Support After Modest Decline Eaton Vance Global Diversified Equity Income Fund EXG Modest Pullback as Shares Test Support Zone Pagaya Technologies Warrants PGYWW Climb 1255 as LowPriced Warrants Test Key 006 Level Idaho Chip Manufacturer Surges to 1 Trillion Market Cap in Record 48Day Run China Tightens CrossBorder Stock Trading Regulations Key Details Voya Financial Reports Earnings Growth Across All Three Business Segments Trump Urges Supreme Court to Intervene on TikTok Ban CRNX Q1 2026 Earnings Narrowed Loss Per Share Slightly Below Expectations FITBI Q1 2026 Earnings EPS Surges Past Estimates Modest Stock Response DaVita Q1 2026 Earnings EPS Surges Past Estimates by 226 Yet Stock Barely Moves Forte Biosciences Q1 2026 Earnings Prerevenue Biotech Misses EPS Estimates Stock Dips on Narrower Loss Miss LKQ Q1 2026 Earnings EPS Misses Estimates Amid Challenging Conditions Stock Edges Higher CanFite Biopharma Q4 2023 Earnings Significant EPS Surprise as Biotech Focuses on Clinical Pipeline